| Literature DB >> 35845023 |
Muhammad Aziz1, Amna Iqbal2, Zohaib Ahmed2, Saad Saleem3, Wade Lee-Smith4, Hemant Goyal5, Faisal Kamal6, Yaseen Alastal1, Ali Nawras1, Douglas G Adler7.
Abstract
Background and study aims The impact of guidewire caliber on endoscopic retrograde pancreatography (ERCP) outcomes are not clear. Recent studies have compared two guidewires, 0.035- and 0.025-inch, in randomized controlled trials (RCTs). We performed a systematic review and meta-analysis of available RCTs to assess if different caliber would change the outcomes in ERCP. Patients and methods A systematic search of PubMed/Medline, Embase, Cochrane, SciELO, Global Index Medicus and Web of Science was undertaken through November 23, 2021 to identify relevant RCTs comparing the two guidewires. Binary variables were compared using random effects model and DerSimonian-Laird approach. For each outcome, risk-ratio (RR), 95 % confidence interval (CI), and P values were generated. P < 0.05 was considered significant. Results Three RCTs with 1079 patients (556 in the 0.035-inch group and 523 in the 0.025-inch group) were included. The primary biliary cannulation was similar in both groups (RR: 1.02, CI: 0.96-1.08, P = 0.60). The overall rates of PEP were also similar between the two groups (RR: 1.15, CI: 0.73-1.81, P = 0.56). Other outcomes (overall cannulation rate, cholangitis, perforation, bleeding, use of adjunct techniques) were also comparable. Conclusions The results of our analysis did not demonstrate a clear benefit of using one guidewire over other. The endoscopist should consider using the guidewire based on his technical skills and convenience. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).Entities:
Year: 2022 PMID: 35845023 PMCID: PMC9286775 DOI: 10.1055/a-1834-7101
Source DB: PubMed Journal: Endosc Int Open ISSN: 2196-9736
Fig.1PRISMA diagram. From: Page MJ, McKenzie JE, Bossuyt PM et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021; 372: 71
Baseline study characteristics and demographics.
|
|
|
| |
| Study period | June 2010 – August 2012 | June 2011 – February 2012 | April 2011 – March 2013 |
| Single/multicenter | Multicenter | Single center | Single center |
| Total participants, n | |||
0.035-inch group | 346 | 50 | 160 |
0.025-inch group | 364 | 50 | 109 |
| Study completion | |||
0.035-inch group | 335 | 50 | 160 |
0.025-inch group | 357 | 50 | 109 |
| Mean age, years (SD) | |||
0.035-inch group | 60 | 67.5 (17.3) | 65.3 (22.2) |
0.025-inch group | 58 | 63.8 (19.1) | 66.8 (17.0) |
| Females, n (%) | |||
0.035-inch group | 168 (50.1 %) | 33 (66.0 %) | 83 (51.9 %) |
0.025-inch group | 186 (51.9 %) | 27 (54.0 %) | 68 (62.4 %) |
| ERCP indication, n (%) | |||
Choledocholithiasis (suspected/established) | 318 | 66 | 155 |
Cholangitis | 105 | NR | 8 |
Benign stricture | 8 | 33 | 12 |
Other | 261 | 1 | 94 |
| Equipment used | |||
0.035-inch group | straight 5-cm hydrophilic tip (Boston Scientific) | 260-cm long wire (Hydrosteer; St. Jude Medical) | 450-cm long wire with outer diameter 0.91 mm, straight tip (Jagwire, Boston Scientific) |
0.025-inch group | straight 7-cm hydrophilic tip (Visiglide, Olympus Corporation) | 270-cm long wire (VisiGlide; Olympus Corporation) | 450-cm long wire with outer diameter 0.65 mm (Boston Scientific) |
NR, not reported; SD, standard deviation.
Outcomes for individual studies.
|
|
|
| |
| Primary biliary cannulation, n (%) | |||
0.035-inch group | 269 (80.3 %) | 40 (80.0 %) | 138 (86.3 %) |
0.025-inch group | 288 (80.7 %) | 40 (80.0 %) | 88 (80.7 %) |
| Overall cannulation, n (%) | |||
0.035-inch group | 306 (91.3 %) | 50 (100.0 %) | 156 (97.5 %) |
0.025-inch group | 326 (91.3 %) | 49 (98.0 %) | 101 (92.7 %) |
| Post-ERCP pancreatitis, n (%) | |||
0.035-inch group | 31 (9.3 %) | 1 (2.0 %) | 4 (2.5 %) |
0.025-inch group | 28 (7.8 %) | 1 (2.0 %) | 3 (2.8 %) |
| Double guidewire cannulation, n (%) | |||
0.035-inch group | 19 (5.7 %) | 1 (2.0 %) | 21 (13.1 %) |
0.025-inch group | 24 (6.7 %) | 5 (10.0 %) | 15 (13.8 %) |
| PD stent placement, n (%) | |||
0.035-inch group | 16 (4.8 %) | NR | 25 (15.6 %) |
0.025-inch group | 24 (6.7 %) | NR | 16 (14.7 %) |
| Precut sphincterotomy, n (%) | |||
0.035-inch group | 31 (9.3 %) | NR | 11 (6.9 %) |
0.025-inch group | 32 (9.0 %) | NR | 9 (8.3 %) |
| Cholangitis, n (%) | |||
0.035-inch group | 5 (1.5 %) | 0 (0 %) | 2 (1.3 %) |
0.025-inch group | 7 (2.0 %) | 0 (0 %) | 0 (0 %) |
| Bleeding, n (%) | |||
0.035-inch group | 6 (1.8 %) | NR | 1 (0.6 %) |
0.025-inch group | 10 (2.8 %) | NR | 2 (1.8 %) |
| Perforation, n (%) | |||
0.035-inch group | 3 (0.9 %) | 0 (0 %) | 0 (0 %) |
0.025-inch group | 5 (1.4 %) | 0 (0 %) | 0 (0 %) |
PD, pancreatic duct.
Fig. 2Forest plot comparing the 0.035– and 0.025-inch guidewire for rates of a primary biliary cannulation; and b post-ERCP pancreatitis.
Fig. 3Forest plot comparing the 0.035– and 0.025-inch guidewire for rates of: a overall cannulation; b double guidewire cannulation; c pancreatic duct stent placement; and d precut sphincterotomy.
Fig. 4Forest plot comparing the 0.035– and 0.025-inch guidewire for rates of: a cholangitis; b bleeding; and c perforation.